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Olopatadine hydrochloride (OLP) is an antihistaminic drug
with selective histamine H1 receptor antagonist activity.1 OLP
has inhibitory effects on the production of various chemical medi-
ators and cytokines, such as interleukin (IL)-6, IL-8, and tumor ne-
crosis factor-a (TNF-a).2,3 It inhibits TNF-a release from human
conjunctival mast cells, and consequently decreases CD54 expres-
sion on the cells.3 In the skin, the ability of Langerhans cells (LCs),
epidermal antigen-presenting dendritic cells (DCs), to present
hapten to T cells is reduced by OLP with decreased expression of
major histocompatibility complex class II and co-stimulatory mol-
ecules.4 Furthermore, OLP downmodulates CCL17/TARC produc-
tion by LCs as well as keratinocytes (KCs), as OLP at a
concentration of 106 or 105 mol/L suppresses the IFN-g/TNF-a-
augmented production of CCL17 from HaCaT cells and the mRNA
expression of CCL17 and CCL22 in mature bone marrow DCs, a
mimicry of pure LCs.5 More recently, OLP was reported to decrease
tissue IL-31 and thymic stromal lymphopoietin levels in an atopic
dermatitis (AD) mouse model.6,7 An in vivo study also showed
decreased serum levels of CCL17 and CCL22 in AD patients after
treatment with OLP.8 These ﬁndings suggest that OLP downmodu-
lates Th2-mediated skin inﬂammation at least in part by inter-
fering with the antigen-presenting and chemokine-producing
abilities of DCs. However, it remains to be elucidated whether
OLP directly regulate the action of Th2 cells. In this study, we
thus studied the effect of OLP on T cell chemotactic activity toward
the Th2 chemokine, CCL17.
The study was approved by the ethical committee of Hama-
matsu University School of Medicine. Seven patients with AD
who had not been treated with oral antihistaminic or immuno-
suppressive drugs were enrolled in this study after providing
their informed consent. CD4þ T cells were isolated from periph-
eral blood mononuclear cells (PBMCs) by negative selection using
a CD4þ T Cell Isolation Kit II (Miltenyi Biotec, Auburn, CA, USA)
and complete RPMI-1640 was used as the culture medium.9 Cells
were incubated with or without 1  106 M or 1  105 M OLP
hydrochloride (Kyowa-Kirin, Tokyo, Japan) in complete RPMI-
1640 for 8 h. Actually, the concentration of 1  105 M is ratherPeer review under responsibility of Japanese Society of Allergology.
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of 10 mg olopatadine chloride. However, 1  106 M is nearly
actual concentration of Cmax. The cell viabilities had been
conﬁrmed by Trypan blue staining, that showed no toxic effects
of 1  106 and 1  105 M olopatadine. Time-lapse images of
cell migration during chemotaxis were observed directly using
EZ-TAXIScan, an optically accessible, horizontal real-time chemo-
taxis analyzer, via a charge-coupled device (CCD) camera (GE
Healthcare, Tokyo, Japan). The migration traces of CD4þ T cells
were plotted against time and distance, and velocity was calcu-
lated by ImageJ software (National Institutes of Health, Bethesda,
Maryland, USA).
As shown in Fig. 1a, representative chemotaxis data with CD4þ
T cells from an AD patient demonstrated that CD4þ T cells
without OLP incubation migrated towards CCL17 in a straightfor-
ward manner (black lines). However, cells incubated with
1  105 M OLP (blue lines) exhibited random movement. Treat-
ment with 1  106 M OLP yielded moderately random move-
ment (red lines). In all 7 patients, the mean velocity levels of
CD4þ T cells toward CCL17 were signiﬁcantly suppressed by
1  105 M OLP compared with non-treated controls (Fig. 1b)
(P ¼ 0.001> compared with the non-treated group). Pearson's
correlation test has been demonstrated between TARC and Veloc-
ity. The correlation coefﬁcient is 0.97 that means strong positive
correlation. In addition, the olopatadine effectively inhibited che-
moattraction of CD4þ T cells toward TARC in the patient with
lower serum TARC. These ﬁgures were added as the supplemental
data (Supplementary Fig. 1a, b). Olopatadine also inhibits the ac-
tivity of CD4þ T cell chemoattractant from healthy control more
strongly toward TARC compared to AD patients. The representa-
tive result has been added as the supplemental data
(Supplementary Fig. 2).
CCL17 is a ligand for the CCR4 chemokine receptor, and the
expression of CCR4 on T cells is increased in patients with AD.10
Therefore, we examined the modulatory effect of OLP on CCR4
expression in CD4þ T cells from 7 AD patients. The cell surface
expression of CCR4 on CD4þ T cells was determined by ﬂow cyto-
metric analysis using FACSCalibur (Becton Dickinson).9 The mean
ﬂuorescent intensity (MFI) levels of CCR4 on CD4þ T cells were
moderately but signiﬁcantly decreased after incubation with OLP
at 1  106 M or 1  105 M as compared with the non-treated
group (P ¼ 0.03) (Fig. 2a).
F-actin plays a crucial role in T cell chemotactic movement. To
test whether OLP affects F-actin polymerization, ﬂow cytometricevier B.V. All rights reserved.
Fig. 1. OLP decreases velocities of CD4þ T cells toward CCL17/TARC. The velocities of CD4þ T cells from a representative AD patient are shown (a). The mean velocities of CD4þ T cells
in 7 AD patients are statistically analyzed with Dunnett's method (b). *P < 0.01.
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din binds to polymeric and oligomeric forms of actin, but not to
monomeric actin, the level of polymerized actin was determined
by staining cells with phalloidin.11 The MFIs of phalloidin were
lower in CD4þ T cells treated with 1  105 OLP than in non-
treated cells (Fig. 2b), indicating inhibition of F-actin polymeriza-
tion by OLP.
In this study, we found that OLP downmodulates not only the
CCL17/TARC production by LCs and HaCaT KCs, but also the chemo-
attractive activity of Th2 cells towards CCL17. These two modula-
tory actions of OLP concerning inﬁltration of Th2 cells may lead
to suppression of inﬂammatory events occurring in the AD lesion.The inhibitory effects of OLP may be exerted via the downregula-
tion of CCR4 expression and the hindrance of F-actin polymeriza-
tion. Serum CCL17/TARC level is regarded as a biomonitoring
marker that reﬂects changes in the skin condition of ADmore accu-
rately and sensitively than conventional laboratory measures.12
Serum CCL17/TARC concentration signiﬁcantly decreased after
effective treatment in parallel with the improvement of clinical
symptoms, SCORAD index and pruritus score in AD patients.13 In
addition to its suppressive effects on Th2 cells, we have reported
that OLP is a downmodulator of CXCL10-induced Th1/Tc1 chemoat-
traction.9 Our studies suggest that some of antihistamines have
anti-allergic action even on T cell chemotaxis.
Fig. 2. CCR4 MFI of CD4þ T cells from an AD patient (a) and the levels of F-actin. polymerization (b).
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